HEPATOSPLENIC T-CELL LYMPHOMA
Clinical trials for HEPATOSPLENIC T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HEPATOSPLENIC T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for HEPATOSPLENIC T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Matched conditions: HEPATOSPLENIC T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC